Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn.

mAbs - 1 Jan 2000

Bernett Matthew J, Chu Seung Y, Leung Irene, Moore Gregory L, Lee Sung-Hyung, Pong Erik, Chen Hsing, Phung Sheryl, Muchhal Umesh S, Horton Holly M, Lazar Greg A, Desjarlais John R, Szymkowski David E

Abstract excerpt

The CTLA4-Ig fusion proteins abatacept and belatacept are clinically proven immunosuppressants used for rheumatoid arthritis and renal transplant, respectively. Given that both biologics are typically administered chronically by infusion, a need exists for a next-generation CTLA4-Ig with more convenient dosing. We used structure-based protein engineering to optimize the affinity of existing CTLA4-Ig therapeutics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abatacept
Share to Antibody Affinity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthritis, Experimental

Share to B7-1 Antigen

Share to B7-2 Antigen

Share to Immunoconjugates

Share to Immunosuppression Therapy

Share to Receptors, Fc

Source

Open in PubMed Open full text

Identifiers

PMID: 23549103
DOI: 10.4161/mabs.23976
PMCID: PMC4169032

Genes

CTLA4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn.PMID 23549103Read ↗

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.Semantic proximity Read ↗

Dual Immune Checkpoint and Cytokine Receptor Modulation by an Engineered Human CTLA-4/IL-10 Bispecific Fusion ProteinSemantic proximity Read ↗

The Dual Targeting of FcRn and FcγRs via Monomeric Fc Fragments Results in Strong Inhibition of IgG-Dependent Autoimmune Pathologies.Semantic proximity Read ↗

Mechanism of Action and Pharmacokinetics of Approved Bispecific AntibodiesSemantic proximity Read ↗

Next-generation flexible formats of VNAR domains expand the drug platform's utility and developabilitySemantic proximity Read ↗

Discovery 4.0: An Escape-Aware Computational Platform for Resistance-Proofed Chimeric Antigen Receptor DesignSemantic proximity Read ↗

Biologic therapies for lupus nephritis: a systematic review of efficacy, safety, and cost-effectivenessSemantic proximity Read ↗

Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cellsSemantic proximity Read ↗

Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.Semantic proximity Read ↗

Computational modeling and optimization of peptide-based CAR-T cell receptors targeting CD19 for enhanced efficacy and minimized toxicitySemantic proximity Read ↗

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.Semantic proximity Read ↗

Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamilySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.